

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|-----------------|
| Name of entity | CARDIEX LIMITED |
| ABN | 81 113 252 234 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|------------------|
| Name of Director | Charlie Taylor |
| Date of last notice | 31 December 2024 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|---|
| Direct or indirect interest | Direct and Indirect interest |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | <u>CW Taylor Family Trust</u> Charlie Taylor is a controller and beneficiary of this entity. |
| Date of change | 9 May 2025 |
| No. of securities held prior to change | <u>Direct</u> <ul style="list-style-type: none"> 1,000,000 Quoted Options at \$0.20 expiring 30 November 2025 |
| Class | As above |
| Number acquired | <u>Indirect</u> CW Taylor Family Trust <ul style="list-style-type: none"> 833,334 Fully Paid Ordinary Shares at \$0.09 833,334 Quoted Options at \$0.20 expiring 30 November 2025 |
| Number disposed | NIL |

Appendix 3Y
Change of Director's Interest Notice

| | |
|---|---|
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | Acquired <u>Indirect</u> CW Taylor Family Trust <ul style="list-style-type: none"> \$75,000 being \$0.09 per share, with free attaching 1:1 Quoted Options – Director December 2024 Placement participation approved at the Cardiex May 2025 EGM. |
| No. of securities held after change | <u>Direct</u> <ul style="list-style-type: none"> 1,000,000 Quoted Options at \$0.20 expiring 30 November 2025 <u>Indirect</u> CW Taylor Family Trust <ul style="list-style-type: none"> 833,334 Fully Paid Ordinary Shares at \$0.09 833,334 Quoted Options at \$0.20 expiring 30 November 2025 |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Acquired <u>Indirect</u> CW Taylor Family Trust <ul style="list-style-type: none"> Director December 2024 Placement participation approved at the Cardiex May 2025 EGM. |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

| | |
|--|----------------------------------|
| Detail of contract | N/A as no interest in contracts. |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| Interest after change | N/A |

+ See chapter 19 for defined terms.

For personal use only

Part 3 – ⁺Closed period

| | |
|---|------------------------------|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | N/A as no securities traded. |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

⁺ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|-----------------|
| Name of entity | CARDIEX LIMITED |
| ABN | 81 113 252 234 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|------------------|
| Name of Director | Niall Cairns |
| Date of last notice | 31 December 2024 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|--|
| Direct or indirect interest | Direct & Indirect |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | <p><u>C2 Ventures Pty Ltd</u> Niall Cairns is a controller of this entity.</p> <p><u>Carnethy Evergreen Pty Ltd</u> Niall Cairns is the controller of this entity.</p> <p><u>Carnethy Investments Pty Ltd</u> Niall Cairns is the controller of this entity.</p> |
| Date of change | 9 May 2025 |

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|---|
| <p>No. of securities held prior to change</p> | <p><u>Direct Interests</u></p> <ul style="list-style-type: none"> • 2,000,000 Performance Rights expiring 30 November 2027 • 1,000,000 FPO <p><u>C2 Ventures Pty Ltd</u></p> <ul style="list-style-type: none"> • 122,776,955 FPO • 1,500,000 Convertible Note Options exercisable at \$0.45 each expiring 31 August 2026 • 32,417,520 Quoted Options at \$0.20 expiring 30 November 2025 <p><u>Carnethy Evergreen Pty Ltd</u></p> <ul style="list-style-type: none"> • 1,937,702 FPO • 200,000 Convertible Note Options exercisable at \$0.45 each expiring 31 August 2026 • 475,902 Quoted Options at \$0.20 expiring 30 November 2025 <p><u>Carnethy Investments Pty Ltd</u></p> <ul style="list-style-type: none"> • 8,465,310 FPO • 2,621,771 Quoted Options at \$0.20 expiring 30 November 2025 |
| <p>Class</p> | <p>As above</p> |
| <p>Number acquired</p> | <p><u>Direct Interests</u></p> <ul style="list-style-type: none"> • 7,500,000 Performance rights: <ol style="list-style-type: none"> a) 2,500,000 vest upon the Company's share price reaching \$0.20, expiring 09 May 2030 b) 2,500,000 vest upon the Company's share price reaching \$0.25, expiring 09 May 2030 c) 2,500,000 vest upon the Company's share price reaching \$0.30, expiring 09 May 2030 |

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

| | |
|---|---|
| <p>Number disposed</p> | <p>NIL</p> |
| <p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p> | <p>Acquired <u>Direct</u></p> <ul style="list-style-type: none"> • Performance Rights approved at the Cardix 2025 EGM issued for NIL cash consideration and an estimated value of the Performance Rights being \$533,250 |
| <p>No. of securities held after change</p> | <p><u>Direct Interests</u></p> <ul style="list-style-type: none"> • 2,000,000 Performance Rights expiring 30 November 2027 • 7,500,000 Performance Rights expiring 9 May 2030 • 1,000,000 FPO <p><u>C2 Ventures Pty Ltd</u></p> <ul style="list-style-type: none"> • 122,776,955 FPO • 1,500,000 Convertible Note Options exercisable at \$0.45 each, expiring 31 August 2026 • 32,417,520 Quoted Options at \$0.20 expiring 30 November 2025 <p><u>Carnethy Evergreen Pty Ltd</u></p> <ul style="list-style-type: none"> • 1,937,702 FPO • 200,000 Convertible Note Options exercisable at \$0.45 each, expiring 31 August 2026 • 475,902 Quoted Options at \$0.20 expiring 30 November 2025 <p><u>Carnethy Investments Pty Ltd</u></p> <ul style="list-style-type: none"> • 8,465,310 FPO • 2,621,771 Quoted Options at \$0.20 expiring 30 November 2025 |
| <p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p> | <p>Acquired <u>Direct Interests</u></p> <ul style="list-style-type: none"> • Performance Rights issued following shareholder approval received on 9 May 2025 EGM. |

+ See chapter 19 for defined terms.

For personal use only

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|----------------------------------|
| Detail of contract | N/A as no interest in contracts. |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| Interest after change | N/A |

Part 3 – ⁺Closed period

| | |
|---|------------------------------|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | N/A as no securities traded. |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

⁺ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|-----------------|
| Name of entity | CARDIEX LIMITED |
| ABN | 81 113 252 234 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|------------------|
| Name of Director | Craig Cooper |
| Date of last notice | 31 December 2024 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|---|
| Direct or indirect interest | Direct & Indirect |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | <u>C2 Ventures Pty Ltd</u> Craig Cooper is a controller of this entity. |
| Date of change | 9 May 2025 |
| No. of securities held prior to change | <u>Direct Interests</u> <ul style="list-style-type: none"> • 2,000,000 Performance Rights expiring 30 November 2027 • 11,509,863 FPO • 3,303,288 Quoted Options at \$0.20 expiring 30 November 2025 <u>C2 Ventures Pty Ltd</u> <ul style="list-style-type: none"> • 122,776,955 FPO • 1,500,000 Convertible Note Options exercisable at \$0.45 each expiring 31 August 2026 • 32,417,520 Quoted Options at \$0.20 expiring 30 November 2025 |
| Class | As above |

Appendix 3Y
Change of Director's Interest Notice

| | |
|---|--|
| <p>Number acquired</p> | <p><u>Direct</u></p> <ul style="list-style-type: none"> • 7,500,000 Performance rights: <ul style="list-style-type: none"> a) 2,500,000 vest upon the Company's share price reaching \$0.20, expiring 09 May 2030 b) 2,500,000 vest upon the Company's share price reaching \$0.25, expiring 09 May 2030 c) 2,500,000 vest upon the Company's share price reaching \$0.30, expiring 09 May 2030 |
| <p>Number disposed</p> | <p>NIL</p> |
| <p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p> | <p>Acquired Direct</p> <ul style="list-style-type: none"> • Performance Rights approved at the Cardiex 2025 EGM issued for NIL cash consideration and an estimated value of the Performance Rights being \$533,250 |
| <p>No. of securities held after change</p> | <p><u>Direct Interests</u></p> <ul style="list-style-type: none"> • 2,000,000 Performance Rights expiring 30 November 2027 • 7,500,000 Performance Rights expiring 9 May 2030 • 11,509,863 FPO • 3,303,288 Quoted Options at \$0.20 expiring 30 November 2025 <p><u>C2 Ventures Pty Ltd</u></p> <ul style="list-style-type: none"> • 122,776,955 FPO • 1,500,000 Convertible Note Options exercisable at \$0.45 each, expiring 31 August 2026 • 32,417,520 Quoted Options at \$0.20 expiring 30 November 2025 |

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

| | |
|---|---|
| <p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p> | <p>Acquired <u>Direct</u></p> <ul style="list-style-type: none"> • Performance Rights issued following shareholder approval received on 9 May 2025 EGM. |
|---|---|

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|----------------------------------|
| Detail of contract | N/A as no interest in contracts. |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| Interest after change | N/A |

Part 3 – ⁺Closed period

| | |
|---|------------------------------|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | N/A as no securities traded. |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

+ See chapter 19 for defined terms.

For personal use only